Authors
Latest:
Advancing Myeloma Treatment With Blood-Based MRD TestingIn this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Latest:
JAK Inhibitors and Resistance in MyelofibrosisAnthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.
Latest:
c-Met as a Biomarker in Gastric/GEJ CancersJohn Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.
Latest:
Trastuzumab Deruxtecan Shows Clinical Activity in HER2+ Solid TumorsFunda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
SHP2 Inhibitors Undergo Exploration in CombinationsMelissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.
Latest:
ENDOLA Study Demonstrates Promise of Olaparib Triplet in Endometrial CancerAn olaparib triplet demonstrated efficacy in patients with recurrent advanced or metastatic endometrial cancer treated in the ENDOLA clinical trial.
Latest:
ESMO 2024: DESTINY-Breast12 UpdatesPanelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.
Latest:
Ovarian Cancer Awareness Month: Strides in Up-front and Maintenance TherapyGizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.
Latest:
Utilizing MRD Testing in the Myeloma SpaceGayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.
Latest:
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate CancerArun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Latest:
POLESTAR Results Show PFS Benefit of Aumolertinib in NSCLCAumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.
Latest:
Nirogacestat Shows Statistically Significant Improvements in Desmoid TumorsMrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.
Latest:
Relapsed/Refractory CLL: Practical Advice and Future Directions in CareA key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Latest:
Evaluating Tumor Lysis Syndrome in CLL/SLL Treated With VenetoclaxYannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Latest:
Remote Monitoring Improves Management of Symptoms in Patients With Lung Cancer After SurgeryBrett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Sequential ADCs in Breast Cancer: A Real-World LookLaura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.
Latest:
Future Directions and Unmet Needs in T-ALLBijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr WanderIn this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Latest:
Pandemic Leads to Delays in Crucial Early Cancer Screening TestsClayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
Latest:
Addressing Clinical Trial Challenges in the Outpatient SettingThe national shortage of nurses and health care support staff has spilled over to the clinical research space.
Latest:
Important Safety Data Evaluated in Meta-Analysis of MyelofibrosisJan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Latest:
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell CarcinomaRyan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
